Notícias e Atividades da Contineum Therapeutics

Contineum Therapeutics é uma empresa listada sob o símbolo CTNM (US).

Veja o organograma con seus 23 executivos principais

Biografias mais buscadas da Contineum Therapeutics

• Carmine Stengone, Director, President and Chief Executive Officer
• Evert Schimmelpennink, Director
• Olivia Ware, Director

Recentes movimentos de executivos em Contineum Therapeutics

• Timothy Watkins Contineum, ingressou na Companhia como Chief Medical Officer  (Notícia publicada em 29 de abril de 2025).
• Diego Miralles, ingressou na Companhia como Director  (Notícia publicada em 18 de março de 2025).

Criar um alerta
para seguir os movimentos de executivos da Contineum Therapeutics.

Contineum Therapeutics possui 2.350 concorrentes concorrentes Astellas Gene Therapies (Estados Unidos), Eurofins (Luxemburgo) e Lonza (Suíça).

Popular M&A news in Biotecnologia

• Eli Lilly has announced the acquisition of Verve Therapeutics  (publicado em 17 de junho de 2025).
• Sirius Therapeutics acaba de anunciar uma arrecadação de fundos de 50 milhões de dólares. (publicado em 16 de junho de 2025).
• BioNTech has announced the acquisition of CureVac  (publicado em 12 de junho de 2025).

Outros contatos sugeridos na indústria do Biotecnologia

• Sandra Smith - Senior Vice President, Clinical Solutions & Strategic Partnerships da WIRB-Copernicus Group
• Jasbir Seehra - Chief Executive Officer and Chairman of the Board da Keros Therapeutics
• Deepika Verma - Associate Director of Data Science and Digitalization da Wheeler Bio

Saiba mais sobre a indústria do Biotecnologia

Últimos comunicados de imprensa de Contineum Therapeutics

• Contineum Therapeutics Initiates Patient Dosing in Phase 1b Positron Emission Tomography (PET) Trial of PIPE-791 | Contineum Therapeutics
• Contineum Therapeutics to Attend the 7th Annual Evercore HealthCONx Conference | Contineum Therapeutics
• Contineum Therapeutics Expands Clinical Development of PIPE-791 With FDA Authorization of Its Investigational New Drug (IND) Application for Chronic Pain | Contineum Therapeutics
• Contineum Therapeutics to Attend Upcoming Investor Conferences | Contineum Therapeutics
• News Releases | Contineum Therapeutics
• News Releases | Contineum Therapeutics
• Contineum Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights | Contineum Therapeutics
• Contineum Therapeutics to Present at Multiple Upcoming Investor Conferences | Contineum Therapeutics
• Contineum Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights | Contineum Therapeutics
• Contineum Therapeutics Announces Publication of Encouraging Data in the Proceedings of the National Academy of Sciences on PIPE-307, Its M1 Receptor Selective Inhibitor, in Clinical Development for Relapse-Remitting Multiple Sclerosis | Contineum Therapeu
• View more press releases Close

Redes sociais sobre Contineum Therapeutics

• Contineum Therapeutics na Wikipedia, Google News e Yahoo Finance
• Contineum Therapeutics na LinkedIn, Twitter e YouTube